Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCTBiotechnology
+$0.15 today
- Market cap
- $231.73M
- Beta
- 2.35
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$2.77
Volume 0.64M
Average 0.43M
ARCT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.33M fell 35.1% year over year, behind the -33.2% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 36.6% from the prior quarter. Over 3 fiscal years it compounded at -6.0% a year.
Context
- Stock-based compensation amounted to 37.8% of revenue in FY2025, up 10.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -35.1% toward the trailing-twelve-month pace of -33.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 25.41M USD
- Year-over-year change
- -33.1%
- 4-year CAGR
- -3.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.41M | -33.1% |
| FY2024 | 2024-12-31 | 37.99M | +9.6% |
| FY2023 | 2023-12-31 | 34.65M | +13.2% |
| FY2022 | 2022-12-31 | 30.61M | +5.9% |
| FY2021 | 2021-12-31 | 28.92M | — |
Stock-Based Compensation vs competitors
How ARCT compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -33.2% is the 7th highest of 9, against a peer median of -20.5%.
- Stock-based compensation amounts to 50.9% of revenue for ARCT, versus a peer median of 12.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $35.22M USD | -20.0% | +6.1% | — | |
| LTM Mar 2026 | $35.01M USD | +17.1% | -21.7% | 53.5% | |
| LTM Mar 2026 | $33.45M USD | -28.6% | -34.9% | 5.6% | |
| LTM Mar 2026 | $23.07M USD | -33.2% | -6.0% | 50.9% | |
| LTM Mar 2026 | $18.43M USD | +74.9% | -1.1% | 9.6% | |
| LTM Mar 2026 | $17.5M USD | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $14.34M USD | — | -14.0% | 1556.3% | |
| LTM Mar 2026 | $12.56M USD | +183.6% | +171.6% | — | |
| LTM Mar 2026 | $3.06M USD | -44.1% | -45.0% | — | |
| LTM Mar 2026 | €2.03M EUR | -21.0% | — | 15.1% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding ARCT) | — | -20.5% | -17.8% | 12.3% | |
Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (203.67M) | 9.35M | (29.73M) | (80.94M) | (65.78M) |
| Depreciation & Amortization | 1.19M | 1.53M | 2.96M | 3.54M | 3.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 28.92M | 30.61M | 34.65M | 37.99M | 25.41M |
| Change in Working Capital | 32.63M | (12.56M) | 7.38M | (20.81M) | (39.2M) |
| Accounts Receivables | (1.24M) | 603K | (29.3M) | 28.09M | (1.59M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (769K) | (3.11M) | (2.24M) | 1.92M | (2.96M) |
| Other Working Capital | 34.64M | (10.05M) | 38.92M | (50.81M) | (34.65M) |
| Other Non-Cash Items | 5.9M | 3.06M | (33.36M) | 471K | 2.28M |
| Operating Cash Flow | (135.04M) | 31.99M | (18.1M) | (59.75M) | (74.27M) |
| Capital Expenditures | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.41M) | (7.73M) | (2.9M) | (648K) | (230K) |
| Debt Repayment | 46.6M | (5M) | (27.36M) | 0 | 0 |
| Common Stock Issued | 515K | 411K | 609K | 682K | 13.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 902K | 1.73M | 2.67M | 4.74M | 0 |
| Financing Cash Flow | 48.02M | (2.86M) | (24.09M) | 5.42M | 13.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (90.43M) | 21.41M | (45.09M) | (54.98M) | (61.12M) |
| Free Cash Flow | (138.45M) | 24.27M | (21M) | (60.4M) | (74.27M) |
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
Intrinsic Alpha fair value
Locked
Current Price
$8.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.